1. PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant p53 in vivo.
PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant p53 in vivo. SCID mice (n = 5/group) were injected subcutaneouosly with 8226 cells (3 × 107) in RPMI medium along with Matrigel matrix. Following detection of tumor, mice were divided into two groups: the control group that received daily intraperitoneal injection of vehicle (PBS) and the treatment group that received daily intraperitoneal injection of PRIMA-1Met (100 mg/kg). A, tumors were measured in two perpendicular dimensions every alternate day and tumor volumes were calculated (*, P < 0.05). B, survival was evaluated from the first day of treatment until death or an event occurred by using the Kaplan–Meier curve (P = 0.007). C, body weight was measured every alternate day till day 15. D, tumors were isolated from PRIMA-1-Met–treated and control mice and harvested for analysis by Western blot analysis for the expression of p73 and caspase-3. E, immunohistochemical analysis of tumor sections showed that treatment of mice bearing multiple myeloma tumors with PRIMA-1Met resulted in decrease in the proliferation index (Ki-67) and increase in the apoptotic index (TUNEL), further verifying the ability of PRIMA-1Met to induce apoptosis in multiple myeloma cells in vivo.
Manujendra N. Saha et al. Mol Cancer Ther 2013;12:
©2013 by American Association for Cancer Research